Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
Pilar Cazorla,1 Mary Mackle,2 Jun Zhao,2 Xianwei Ha,2 Armin Szegedi21Formerly, Merck Rahway, 2Merck, Rahway, NJ, USABackground: In clinical practice, clinicians often need to switch antipsychotic medications in patients with schizophrenia to optimize treatment outcomes. Here, we describe the safety...
Guardado en:
Autores principales: | Mackle M, Cazorla P, Zhao J, Ha X, Szegedi A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e482743f111c49358c612581ca9a0d0f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis
por: Cazorla P, et al.
Publicado: (2013) -
Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao K, et al.
Publicado: (2013) -
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
por: Durgam S, et al.
Publicado: (2017) -
Role of sublingual asenapine in treatment of schizophrenia
por: Citrome L
Publicado: (2011) -
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki K, et al.
Publicado: (2017)